该行认为，新进展是对AK112发展潜力的又一次信心证明，考虑到约70%的NSCLC患者属于非鳞状类别，将该因素纳入AK112的海外市场预测模型后，目前预测AK112在美国市场销售潜力最多增加9亿美元，2028至2033年销售额预测亦上调3%至6%，目标价相应由68港元上调至74港元，评级“增持”。Akeso (09926) opened nearly 3% higher, as of the time of publication, up by 2.93% to HK$70.2, with a turnover of 5.967 million Hong Kong dollars.
According to the WiseNews app, Akeso (09926) opened nearly 3% higher, as of the time of publication, up by 2.93% to HK$70.2, with a turnover of 5.967 million Hong Kong dollars.
JPMorgan released research reports pointing out that Akeso's management revealed that non-squamous cell carcinoma patients have been included in the global Phase III clinical study HARMONi-3 of AK112. They plan to recruit 1,080 patients to evaluate the treatment of first-line (1L) patients with squamous and non-squamous non-small cell lung cancer (NSCLC). In addition to overall survival, progression-free survival will also be included as a new co-primary endpoint.
The bank believes that the new progress is another confidence confirmation of the development potential of AK112. Considering that about 70% of NSCLC patients belong to the non-squamous category, after incorporating this factor into the overseas market forecast model of AK112, the current forecasted sales potential of AK112 in the US market could increase by up to $0.9 billion. Sales forecasts for 2028 to 2033 are also raised by 3% to 6%, with the target price corresponding to an increase from HK$68 to HK$74 and a 'shareholding' rating.
